Literature DB >> 2987602

[Vinyl chloride induced hepatocellular carcinoma].

A Dietz, G Langbein, W Permanetter.   

Abstract

On the occasion of a hitherto unique observation of three hepatocellular carcinomas in workers of the same industrial plant within 7 years following long-term exposure to vinylchloride, the characteristics are discussed of a chemical carcinogenesis leading to two different malignant tumours: haemangiosarcoma and hepatocellular carcinoma. This carcinogenic sequence has been predicted by animal studies. It is not known why the transformation of hepatocytes into carcinoma is far rarer than of sinusoidal cells into sarcoma. Whereas the hepatocellular carcinoma predominantly develops in association with cirrhosis, vinyl chloride is able to cause cancer directly without other known co-carcinogenic agents. This hepatic carcinogenicity is dose-dependent. After the introduction of industrial prevention measures, a new initiation of the tumour is improbable. Nevertheless, because of its long latency period, estimated between 5 and 20 years, clinical manifestations are still possible. An early diagnosis by sonography and computertomography, possibly combined with puncture, in exposed persons or those formerly at high risk is conceivable, while laboratory data, even tumour markers are unreliable. Its fulminant course does not differ from that of other hepatocellular carcinomas and has until now hindered successful treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987602     DOI: 10.1007/bf01731976

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  25 in total

1.  [CONTRIBUTION TO THE STUDY OF DISEASES CAUSED BY VINYL CHLORIDE].

Authors:  I SUCIU; I DREJMAN; M VALASKAI
Journal:  Med Interna (Bucur)       Date:  1963-08

2.  [Drug-induced liver lesions].

Authors:  R Teschke
Journal:  Dtsch Med Wochenschr       Date:  1983-02-04       Impact factor: 0.628

3.  Acro-osteolysis occurring in men engaged in the polymerization of vinyl chloride.

Authors:  D K Harris; W G Adams
Journal:  Br Med J       Date:  1967-09-16

4.  [Acro-osteolysis of occupational origin].

Authors:  A Marin; J Strauss; R Michiels; J P Benoit; R Baltié; C Pierre
Journal:  Rev Rhum Mal Osteoartic       Date:  1967-06

5.  [A syndrome of acro-osteolysis of occupational origin, a finding new to France].

Authors:  A Chatelain; P Motillon
Journal:  J Radiol Electrol Med Nucl       Date:  1967-05

6.  Development of hepatic angiosarcoma in man induced by vinyl chloride, thorotrast, and arsenic. Comparison with cases of unknown etiology.

Authors:  H Popper; L B Thomas; N C Telles; H Falk; I J Selikoff
Journal:  Am J Pathol       Date:  1978-08       Impact factor: 4.307

7.  [Vinyl chloride-induced angiosarcoma and hepato-cellular carcinoma of the liver (author's transl)].

Authors:  D Koischwitz; W K Lelbach; K Lackner; D Hermanutz
Journal:  Rofo       Date:  1981-03

8.  Characteristics of cases of angiosarcoma of the liver among vinyl chloride workers in the United States.

Authors:  C W Heath; H Falk; J L Creech
Journal:  Ann N Y Acad Sci       Date:  1975-01-31       Impact factor: 5.691

9.  Vinyl chloride-induced hepatic lesions in man and rodents. A comparison.

Authors:  H Popper; C Maltoni; I J Selikoff
Journal:  Liver       Date:  1981-03

10.  Recent findings on the carcinogenicity of chlorinated olefins.

Authors:  C Maltoni
Journal:  Environ Health Perspect       Date:  1977-12       Impact factor: 9.031

View more
  2 in total

1.  Evaluation in vinyl chloride monomer-exposed workers and the relationship between liver lesions and gene polymorphisms of metabolic enzymes.

Authors:  Shou-Min Zhu; Xue-Feng Ren; Jun-Xiang Wan; Zhao-Lin Xia
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

2.  Evaluation of liver enzyme levels in workers exposed to vinyl chloride vapors in a petrochemical complex: a cross-sectional study.

Authors:  Mir Saeed Attarchi; Omid Aminian; Mandana Dolati; Maria Mazaheri
Journal:  J Occup Med Toxicol       Date:  2007-08-08       Impact factor: 2.646

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.